Segment disclosures

Company overview

STREAMEX CORP.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

11 dimension combinations 94 retained observations 18 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Product · Neuro Clear Technologies Inc Neuro Clear

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:NeuroClearTechnologiesIncNeuroClearMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211115Open filing evidence
2021-01-01 – 2021-09-300 USD20211115Open filing evidence
2021-04-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-03-310 USD20210517Open filing evidence

Product · Viral Clear

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:ViralClearMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211115Open filing evidence
2021-01-01 – 2021-09-300 USD20211115Open filing evidence
2021-04-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-03-310 USD20210517Open filing evidence

Product · Corporate

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=us-gaap:CorporateMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-30100000 USD20211115Open filing evidence
2021-01-01 – 2021-09-30414000 USD20211115Open filing evidence
2021-04-01 – 2021-06-30199000 USD20210811Open filing evidence
2021-01-01 – 2021-06-30314000 USD20210811Open filing evidence
2021-01-01 – 2021-03-31115367 USD20210517Open filing evidence

Service · Neuro Clear Technologies Inc Neuro Clear

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ServiceMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:NeuroClearTechnologiesIncNeuroClearMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211115Open filing evidence
2021-01-01 – 2021-09-300 USD20211115Open filing evidence
2021-04-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-03-310 USD20210517Open filing evidence

Service · Viral Clear

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ServiceMember;us-gaap:StatementBusinessSegmentsAxis=bsgm:ViralClearMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-300 USD20211115Open filing evidence
2021-01-01 – 2021-09-300 USD20211115Open filing evidence
2021-04-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-06-300 USD20210811Open filing evidence
2021-01-01 – 2021-03-310 USD20210517Open filing evidence

Service · Corporate

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ServiceMember;us-gaap:StatementBusinessSegmentsAxis=us-gaap:CorporateMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-308000 USD20211115Open filing evidence
2021-01-01 – 2021-09-3019000 USD20211115Open filing evidence
2021-04-01 – 2021-06-308000 USD20210811Open filing evidence
2021-01-01 – 2021-06-3011000 USD20210811Open filing evidence
2021-01-01 – 2021-03-312680 USD20210517Open filing evidence

Bio Sig AI

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=bsgm:BioSigAIMember
PeriodValueUnitFiledEvidence
2023-04-01 – 2023-06-300 USD20230814Open filing evidence
2023-01-01 – 2023-06-300 USD20230814Open filing evidence
2022-04-01 – 2022-06-300 USD20230814Open filing evidence
2022-01-01 – 2022-06-300 USD20230814Open filing evidence

Neuro Clear Technologies Inc Neuro Clear

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=bsgm:NeuroClearTechnologiesIncNeuroClearMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-03-310 USD20230515Open filing evidence
2022-01-01 – 2022-12-310 USD20230331Open filing evidence
2022-07-01 – 2022-09-300 USD20221114Open filing evidence
2022-01-01 – 2022-09-300 USD20221114Open filing evidence
2022-04-01 – 2022-06-300 USD20220815Open filing evidence
2022-01-01 – 2022-06-300 USD20220815Open filing evidence
2022-01-01 – 2022-03-310 USD20230515Open filing evidence
2021-01-01 – 2021-12-310 USD20230331Open filing evidence
2021-07-01 – 2021-09-300 USD20221114Open filing evidence
2021-01-01 – 2021-09-300 USD20221114Open filing evidence
2021-04-01 – 2021-06-300 USD20220815Open filing evidence
2021-01-01 – 2021-06-300 USD20220815Open filing evidence
2021-01-01 – 2021-03-310 USD20220516Open filing evidence
2020-01-01 – 2020-12-310 USD20220331Open filing evidence

Viral Clear

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=bsgm:ViralClearMember
PeriodValueUnitFiledEvidence
2023-04-01 – 2023-06-300 USD20230814Open filing evidence
2023-01-01 – 2023-06-300 USD20230814Open filing evidence
2023-01-01 – 2023-03-310 USD20230515Open filing evidence
2022-01-01 – 2022-12-310 USD20230331Open filing evidence
2022-07-01 – 2022-09-300 USD20221114Open filing evidence
2022-01-01 – 2022-09-300 USD20221114Open filing evidence
2022-04-01 – 2022-06-300 USD20230814Open filing evidence
2022-01-01 – 2022-06-300 USD20230814Open filing evidence
2022-01-01 – 2022-03-310 USD20230515Open filing evidence
2021-01-01 – 2021-12-310 USD20230331Open filing evidence
2021-07-01 – 2021-09-300 USD20221114Open filing evidence
2021-01-01 – 2021-09-300 USD20221114Open filing evidence
2021-04-01 – 2021-06-300 USD20220815Open filing evidence
2021-01-01 – 2021-06-300 USD20220815Open filing evidence
2021-01-01 – 2021-03-310 USD20220516Open filing evidence
2020-01-01 – 2020-12-310 USD20220331Open filing evidence

Viral Clear Pharmaceuticals Inc

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=BSGM:ViralClearPharmaceuticalsIncMember
PeriodValueUnitFiledEvidence
2024-04-01 – 2024-06-3013000 USD20250815Open filing evidence
2024-01-01 – 2024-06-3027000 USD20250815Open filing evidence
2024-01-01 – 2024-03-3114000 USD20250519Open filing evidence
2023-01-01 – 2023-12-3118000 USD20250415Open filing evidence

Corporate

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=us-gaap:CorporateMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30-146000 USD20260814Open filing evidence
2026-01-01 – 2026-06-30-146000 USD20260814Open filing evidence
2024-01-01 – 2024-12-3140000 USD20260331Open filing evidence
2024-01-01 – 2024-09-3027000 USD20251114Open filing evidence
2024-04-01 – 2024-06-3013000 USD20240814Open filing evidence
2024-01-01 – 2024-06-3027000 USD20240814Open filing evidence
2024-01-01 – 2024-03-3114000 USD20240520Open filing evidence
2023-01-01 – 2023-12-3118000 USD20240416Open filing evidence
2023-07-01 – 2023-09-301000 USD20241114Open filing evidence
2023-01-01 – 2023-09-306000 USD20241114Open filing evidence
2023-04-01 – 2023-06-300 USD20230814Open filing evidence
2023-01-01 – 2023-06-305000 USD20240814Open filing evidence
2023-01-01 – 2023-03-315000 USD20240520Open filing evidence
2022-01-01 – 2022-12-31286000 USD20240416Open filing evidence
2022-07-01 – 2022-09-30135000 USD20231114Open filing evidence
2022-01-01 – 2022-09-30151000 USD20231114Open filing evidence
2022-04-01 – 2022-06-308000 USD20230814Open filing evidence
2022-01-01 – 2022-06-3016000 USD20230814Open filing evidence
2022-01-01 – 2022-03-318000 USD20230515Open filing evidence
2021-01-01 – 2021-12-31441000 USD20230331Open filing evidence
2021-07-01 – 2021-09-30108000 USD20221114Open filing evidence
2021-01-01 – 2021-09-30433000 USD20221114Open filing evidence
2021-04-01 – 2021-06-30207000 USD20220815Open filing evidence
2021-01-01 – 2021-06-30325000 USD20220815Open filing evidence
2021-01-01 – 2021-03-31118000 RestatedUSD20220516Open filing evidence
2020-01-01 – 2020-12-310 USD20220331Open filing evidence